Redhill Biopharma Ltd (RDHL)

9.86
0.13 1.30
NASDAQ : Health Care
Prev Close 9.99
Open 9.85
Day Low/High 9.85 / 10.00
52 Wk Low/High 8.10 / 17.09
Volume 33.97K
Avg Volume 57.80K
Exchange NASDAQ
Shares Outstanding 17.06M
Market Cap 168.02M
EPS -2.30
P/E Ratio 51.84
Div & Yield N.A. (N.A)

Latest News

RedHill Biopharma Announces Poster Presentation Of The Positive RHB-105 Phase III Results For H. Pylori Infection At Digestive Disease Week 2017

RedHill Biopharma Reports 2017 First Quarter Financial Results

RedHill Biopharma To Host First Quarter 2017 Financial Results Conference Call On May 3, 2017

RedHill Biopharma Announces Enrollment Of Last Patient In The BEKINDA® Phase II Study For IBS-D

RedHill Biopharma Announces Peer-Reviewed Publication Of The Positive YELIVA® Phase I Study Results In Advanced Solid Tumors

RedHill Biopharma To Host R&D Day On BEKINDA® For Acute Gastroenteritis And IBS-D

RedHill Biopharma Receives Notice Of Allowance For Two Additional U.S. Patents Covering BEKINDA®

RedHill Biopharma And IntelGenx Announce Marketing Approval Of RIZAPORT® For Migraines In Luxembourg

RedHill Biopharma Announces Exclusive U.S. License From Entera Health For Commercial GI Product EnteraGam®

RedHill Biopharma Receives FDA Orphan Drug Designation For YELIVA® For The Treatment Of Cholangiocarcinoma

RedHill Biopharma To Present At BioCentury Future Leaders In The Biotech Industry Conference

RedHill Biopharma To Present At The 2017 MAP Conference

RedHill Biopharma Announces First Patient Dosed In The Open-Label Extension Study To The Phase III Study With RHB-104 For Crohn's Disease

RedHill Biopharma To Present At The BIO-Europe Spring 2017 Conference

RedHill Biopharma's Co-Promotion Partner Concordia Announces U.S. District Court Grants Treble Damages Relating To Donnatal®

3 Small Biotechs That Still Have Upside

3 Small Biotechs That Still Have Upside

Companies developing drugs for cancer, eye problems and pets -- offer untapped value.

RedHill Biopharma Announces Availability Of Its Annual Report On Form 20-F Through Its Website

RedHill Biopharma Reports 2016 Fourth Quarter And Full-Year Financial Results

RedHill Biopharma Completes Treatment Of Last Patient In BEKINDA® Phase III Study For Acute Gastroenteritis

RedHill Biopharma To Host Fourth Quarter And Full-Year 2016 Financial Results Conference Call On February 23, 2017

RedHill Biopharma Announces Enrollment Of Last Patient In BEKINDA® Phase III Study For Acute Gastroenteritis

RedHill Biopharma To Present At The BIO CEO & Investor Conference

RedHill Biopharma Provides 2017 Semi-Annual Business Update

RedHill Biopharma Provides 2017 Semi-Annual Business Update

RedHill Biopharma Announces QIDP Fast-Track Designation Granted By FDA To RHB-104 For Nontuberculous Mycobacteria Infections

RedHill Biopharma Announces QIDP Fast-Track Designation Granted By FDA To RHB-104 For Nontuberculous Mycobacteria Infections

RedHill Biopharma Announces First Dosing In RHB-105 Supportive PK Studies Ahead Of Confirmatory Phase III Study For H. Pylori Infection

RedHill Biopharma Announces First Dosing In RHB-105 Supportive PK Studies Ahead Of Confirmatory Phase III Study For H. Pylori Infection

RedHill Biopharma's RHB-105 Positive Phase III Study Results For H. Pylori Infection Presented At The Innovations In Gastroenterology 2017 Symposium

RedHill Biopharma's RHB-105 Positive Phase III Study Results For H. Pylori Infection Presented At The Innovations In Gastroenterology 2017 Symposium

RedHill Biopharma Announces Exercise Of Stock Options By Directors And Senior Management

RedHill Biopharma Announces Exercise Of Stock Options By Directors And Senior Management

RedHill Biopharma Announces YELIVA® (ABC294640) Abstract Presentation At The 2017 Cholangiocarcinoma Foundation Annual Conference

RedHill Biopharma Announces YELIVA® (ABC294640) Abstract Presentation At The 2017 Cholangiocarcinoma Foundation Annual Conference

RedHill Biopharma Announces New Research Collaboration With Aarhus University For Oncology Drug MESUPRON

RedHill Biopharma Announces New Research Collaboration With Aarhus University For Oncology Drug MESUPRON

RedHill Biopharma To Present The Positive Results Of The First Phase III Study With RHB-105 For H. Pylori Infection At The Innovations In Gastroenterology 2017 Symposium

RedHill Biopharma To Present The Positive Results Of The First Phase III Study With RHB-105 For H. Pylori Infection At The Innovations In Gastroenterology 2017 Symposium

Load More
Quant Rating on 3:59 PM EDT 5/26/2017

D

(Sell)

From Our Partners

Biotech Forum Daily Digest: Analysts Warming To Mylan; Spotlight On Seres Therapeutics
SeekingAlpha

Redhill Biopharma: $10 Biotech Stock With Upcoming Catalysts
SeekingAlpha

Redhill reports Q1 results
SeekingAlpha

Redhill Biopharma (RDHL) R&D Day on BEKINDA (Acute Gastroenteritis and IBS-D) - Slideshow
SeekingAlpha

RedHill's Yeliva shows treatment effect in early-stage cancer study; shares ahead 2% premarket
SeekingAlpha

RedHill to host investor day April 27
SeekingAlpha

RedHill nabs two new patents covering GI med Bekinda
SeekingAlpha

3 Things In Biotech You Should Learn Today: April 15, 2017
SeekingAlpha

IntelGenx and Redhill Biopharma announce marketing approval of RIZAPORT for migraines in Luxembourg
SeekingAlpha

Biotech Forum Daily Digest: Valeant's Continuing Struggles, Spotlight On GlycoMimetics
SeekingAlpha

RedHill nabs exclusive U.S. rights to EnteraGram; shares ahead 3% premarket
SeekingAlpha

RedHill's Yeliva an Orphan Drug for bile duct cancer; shares ahead 7% premarket
SeekingAlpha

RedHill Biopharma: Multiple Drugs In Advanced Phase III Development Provide Substantial Upside
SeekingAlpha

Redhill Keeps The Speciality Dream Alive
SeekingAlpha

2 Must-Have Biotechs For The Approaching 2nd Quarter
SeekingAlpha
TheStreet Quant Rating: D (Sell)

Get the (RDHL)
Report Here

Trending
Now We Have an Idea When the iPhone 8 Will Launch, Thanks to Vacationing Apple Employees
Lowe's Is Getting Absolutely Smoked by Home Depot in One of the Biggest Housing Recoveries Ever
FTC Seen as Set to Block Rite Aid Deal
Nike Hopes People Rally Around These New LGBTQ Themed Rainbow Sneakers
Top Earnings Takeaways for Splunk, Nutanix, Veeva and Marvell